Edelman Joseph's Form 4 filing
Cerevel Therapeutics Holdings, Inc. (CERE) · filed Jul 9, 2021
- Accession no.
- 0001062993-21-006425
- Filed
- Jul 9, 2021, 6:39 PM ET
- Trade date
- Jul 7, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $5.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | Director |
| Perceptive Advisors LLCCIK 0001224962 | Director |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2021 | Common Stock | PPurchaseAcquired | +200,000 | $25.00 | +$5,000,000 | 4,843,095 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.